Page last updated: 2024-09-05

sorafenib and Adenocarcinoma, Clear Cell

sorafenib has been researched along with Adenocarcinoma, Clear Cell in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y	1
Dent, P	1
Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S	1
Dranitsaris, G; Fang, F; Huang, L; Lacouture, ME; Vincent, MD; Yu, J	1
Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D	1

Trials

1 trial(s) available for sorafenib and Adenocarcinoma, Clear Cell

Article	Year
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:8 Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Reproducibility of Results; Risk Factors; Sorafenib; Young Adult	2012

Article

Year

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:8

Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Reproducibility of Results; Risk Factors; Sorafenib; Young Adult

2012

Other Studies

4 other study(ies) available for sorafenib and Adenocarcinoma, Clear Cell

Article	Year
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer biology & therapy, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib	2014
Multi-kinase inhibition in ovarian cancer. Cancer biology & therapy, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib	2014
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer science, 2010, Volume: 101, Issue:12 Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expression Profiling; Humans; Mice; Mice, Nude; Niacinamide; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays	2010
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5 Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A	2007